Public Offerings, Product Launches, and Upcoming Conferences - Analyst Notes on Insulet, CR Bard, Covidien, Thoratec and Hill-Rom

Editor Note: For more information about this release, please scroll to bottom.

Jun 09, 2014, 05:30 ET from Analysts Review

NEW YORK, June 9, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Insulet Corporation (NASDAQ: PODD), CR Bard Inc. (NYSE: BCR), Covidien plc (NYSE: COV), Thoratec Corp. (NASDAQ: THOR) and Hill-Rom Holdings, Inc. (NYSE: HRC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: -- Insulet Corporation Analyst Notes On June 4, 2014, Insulet Corp. (Insulet) announced the pricing of a public offering of $175 million principal amount of convertible senior notes due 2019. According to the Company, the notes will bear an annual interest rate of 2.00% and will mature on June 15, 2019. The Company also granted the underwriter an option to purchase up to an additional $26.25 million principal amount of notes to cover any over-allotments. Insulet estimates the net proceeds from the notes offering to be approximately $169.3 million (after deducting the underwriter's discounts and estimated offering expenses payable by Insulet), and intends to use approximately $120 million of the net proceeds to repurchase approximately $86 million principal amount of its outstanding 3.75% Convertible Senior Notes due 2016 pursuant to individually negotiated transactions. The full analyst notes on Insulet are available to download free of charge at: -- CR Bard Inc. Analyst Notes On June 4, 2014, CR Bard Inc.'s (CR Bard) stock increased by 0.99% to end the day at $147.38. The Company's stock went up 0.25% over the past five trading days compared to the Dow Jones Industrial Average which rose 0.63% and to Standard & Poor's 500 which increased 0.95% during the same trading period. The full analyst notes on CR Bard are available to download free of charge at: -- Covidien plc Analyst Notes On June 3, 2014, Covidien plc (Covidien) announced the European commercial launch and CE Mark of Nellcor™ Respiration Rate System. According to the Company, this technology will give clinicians the ability to monitor a patient's SpO2, pulse rate and respiration rate through a single integrated finger sensor. "This single integrated sensor technology is a significant development in the patient monitoring industry," said Matt Anderson, Vice President and General Manager, Patient Monitoring, Covidien. "It supports Covidien's goal of being on the forefront of cutting-edge medical technology to enable clinicians to provide better patient care." The full analyst notes on Covidien are available to download free of charge at: -- Thoratec Corp. Analyst Notes On June 3, 2014, Thoratec Corp. (Thoratec) announced that it will present at three upcoming investor conferences in June 2014: the Goldman Sachs 35th Annual Global Healthcare Conference on June 10, 2014 at 1:20 p.m. PDT or 4:20 p.m. EDT; the William Blair 34th Annual Growth Stock Conference on June 11, 2014 at 4:40 p.m. CDT and 5:40 p.m. EDT; and the 2014 Wells Fargo Healthcare Conference on June 18, 2014 at 8:55 a.m. EDT or 5:55 a.m. PDT. A webcast of the presentations will be available on the Company's website. The full analyst notes on Thoratec are available to download free of charge at: -- Hill-Rom Holdings, Inc. Analyst Notes On May 28, 2014, Hill-Rom Holdings, Inc. (Hill-Rom) announced its participation in the Goldman Sachs 35th Annual Global Healthcare Conference. The Company will present at the conference on June 11, 2014, at 2:20 p.m. EDT. The live discussion can be accessed through the Company's website, where a recorded replay of the discussion will be available one hour after conclusion of the live event until June 25, 2014. The full analyst notes on Hill-Rom are available to download free of charge at: -- About Analysts Review We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership. =============== EDITOR'S NOTES: =============== 1. This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] 5. For any urgent concerns or inquiries, please contact us at compliance [at] 6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review